New Mediastinal and Hilar Lymphadenopathy After Adjuvant Pembrolizumab in a Patient With Stage III Clear Cell Renal Cell Carcinoma.
The advent of immune checkpoint inhibitors (ICIs) has transformed the management of advanced and high-risk renal cell carcinoma (RCC). In the adjuvant setting, ICIs, such as pembrolizumab, aim to reduce the risk of recurrence following potentially curative nephrectomy.